-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Emerging insights in biology and treatment approaches to Peripheral T cell Lymphomas

Sponsor: Acrotech Pharma
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Combination therapy, Adult, Clinical Practice (Health Services and Quality), Drug development, Elderly, Education, Treatment Considerations, Adverse Events, Biological Processes, Molecular biology, Study Population, Human, Measurable Residual Disease
Friday, December 6, 2024: 11:00 AM-2:00 PM
Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)
Chair:
Swami P. Iyer, MD, The University of Texas MD Anderson Cancer Center
Disclosures:
Iyer: Innate: Research Funding; Dren-Bio: Research Funding; CRISPR: Research Funding; Merck: Research Funding; Acrotech: Research Funding; Seagen: Research Funding; Pfizer: Research Funding; IMPaRT.ai: Current equity holder in private company.
Speakers:
Kate Cwynarski, MBBS, PhD, FRCP, FRCPath, University College London Hospital , Jasmine Zain, MD, City of Hope , Luis Malpica, MD, The University of Texas MD Anderson Cancer Center and Yun Kyoung Tiger, MD, PhD, Rutgers Robert Wood Johnson Medical School
Disclosures:
Cwynarski: Incyte: Consultancy, Speakers Bureau; Kite: Consultancy, Speakers Bureau; AbbVie, Celgene, Atara, Janssen,: Consultancy; Gilead: Consultancy, Speakers Bureau; Roche, Takeda: Consultancy, Speakers Bureau; BMS: Consultancy. Zain: Dren-Bio: Consultancy, Research Funding; Myeloid: Research Funding; Daichi Sankyo: Research Funding; CRISPR Therapeutic: Research Funding; Astex: Research Funding; Kyowa Kirin: Speakers Bureau; Secura Bio: Research Funding; Seattle Genetics: Consultancy. Malpica: Eisai: Research Funding; Dizal: Research Funding.
Peripheral T-cell lymphoma (PTCL) represents a group of heterogeneous and aggressive non-Hodgkin lymphomas with generally poor prognosis. Despite advances in understanding the underlying biology, treatment outcomes have remained suboptimal. This symposium, supported by Acrotech, and provided by the University of Texas MD Anderson Cancer Center with MD Education, will explore groundbreaking therapies and the shifting paradigm in PTCL treatment. Renowned experts will dissect the complexity of PTCL biology, discuss innovative therapeutic strategies, and address the challenges faced in clinical practice. Presentations will include insights into nodal T-cell lymphoma epigenetics, CAR-T cell therapy applications, and novel approaches for rare PTCL subtypes. This educational event promises to answer pivotal questions in PTCL management, focusing on improving patient outcomes and quality of life. With a blend of didactic sessions, interactive panels, and case studies, attendees will be at the forefront of translating emerging research into transformative patient care.